Is Matinas BioPharma Holdings, Inc. (MTNB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 75.2% / 30% | 189.2% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 75.2% / 33% | 189.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 22.9% / 33% | 57.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 75.2% / 33% | 189.2% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 22.9% / 33% | 57.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -151.7% | |
| Return on Assets (ROA) | -38.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$16M |
| Free Cash Flow | -$16M |
| Total Debt | $3M |
| Debt-to-Equity | 36.1 |
| Current Ratio | 3.8 |
| Total Assets | $13M |
Price & Trading
| Last Close | $0.60 |
| 50-Day MA | $0.62 |
| 200-Day MA | $1.08 |
| Avg Volume | 29K |
| Beta | 1.4 |
|
52-Week Range
$0.47
| |
About Matinas BioPharma Holdings, Inc. (MTNB)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Matinas BioPharma Holdings, Inc. (MTNB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Matinas BioPharma Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Matinas BioPharma Holdings, Inc.'s debt ratio?
Matinas BioPharma Holdings, Inc.'s debt ratio is 75.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 22.9%.
What are Matinas BioPharma Holdings, Inc.'s key financial metrics?
Matinas BioPharma Holdings, Inc. has a market capitalization of $4M. Return on equity stands at -151.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.